Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q4 EPS of ($0.44), $0.06 worse than the analyst estimate of ($0.38).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.